ClinicalTrials.gg
CompletedNCT01144455Updated May 11, 2025Results posted

Study of the Safety and Efficacy of TH-302 in Combination With Gemcitabine Compared With Gemcitabine Alone in Previously Untreated Patients With Pancreatic Adenocarcinoma

A Phase 2 interventional study of Gemzar (Gemcitabine) and TH-302 in Pancreatic Adenocarcinoma, sponsored by ImmunoGenesis. Completed at 59 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-11.

Sponsored by ImmunoGenesis · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
214
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to determine whether Gemcitabine versus Gemcitabine and TH-302 are effective in the treatment of subjects with first-line metastatic pancreatic adenocarcinoma.

Read the detailed description

A hypoxic microenvironment is a characteristic of many solid tumors including pancreatic cancer. The presence of hypoxia in solid tumors is associated with a more malignant phenotype and resistance to chemotherapy. The hypoxia-activated prodrug, TH-302, is designed to selectively physiologically target the hypoxic microenvironment. There is an absence of therapeutic options for subjects with metastatic pancreatic cancer. Gemcitabine provides clinical benefit as a single agent, but median survival is about 6 months. Combining gemcitabine with TH-302 may enable the targeting of both the normoxic and hypoxic regions of pancreatic cancer.

02

Conditions studied

  • Pancreatic Adenocarcinoma

Keywords

  • Locally Advanced Unresectable Pancreatic Adenocarcinoma
  • Metastatic Pancreatic Adenocarcinoma
  • Locally Advanced Unresectable or Metastatic Pancreatic Adenocarcinoma
03

In context

Lead sponsor

ImmunoGenesis is the lead sponsor of 8 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. At least 18 years of age
  2. Ability to understand the purposes and risks of the study and has signed a written form approved by the investigator's IRB/Ethics Committee
  3. Locally advanced unresectable or pancreatic ductal adenocarcinoma proven either by histology or cytology previously untreated with chemotherapy or systemic therapy other than:

    • Radiosensitizing doses of 5-fluorouracil;
    • Radiosensitizing doses of gemcitabine if relapse occurred at least 6 months after completion of gemcitabine;
    • chemotherapy if relapse occurred at least 6 months after surgical resection;
    • Adjuvant chemotherapy if relapse occurred at least 6 months after completion of adjuvant chemotherapy.
  4. by 1.1 criteria (at least one target lesion outside of previous radiation fields)
  5. Documentation of disease progression since any prior therapy
  6. performance status of 0 or 1
  7. of at least 3 months
  8. Acceptable liver function:

    1. less than or equal to 1.5 times
    2. (SGOT) and ALT (SGPT) less than or equal to 2.5 times upper limit of normal (ULN); if liver metastases are present, then less than or equal to 5 times ULN is allowed
  9. Acceptable renal function:

    a. Serum creatinine less than or equal to ULN

  10. Acceptable hematologic status (without hematologic support):

    1. ANC greater than or equal to 1500 cells/μL
    2. count greater than or equal to 100,000/μL
    3. greater than or equal to 9.0 g/dL
  11. All women of must have a negative serum pregnancy test and male and female subjects must agree to use effective means of (surgical sterilization or the use or barrier contraception with either a condom or diaphragm in conjunction with spermicidal gel or an IUD) with their partner from entry into the study through 6 months after the last dose

Exclusion criteria

Exclusion Criteria:

  1. (NYHA) Class III or IV, cardiac disease, myocardial infarction within 6 months prior to Day 1, unstable arrhythmia or symptomatic peripheral arterial vascular disease
  2. Known brain, or epidural (unless treated and well controlled for at least 3 months)
  3. Previously treated , except for adequately treated non-melanoma skin cancer, in situ cancer, or other cancer from which the subject has been disease-free for at least 5 years
  4. Severe chronic obstructive or other pulmonary disease with hypoxemia (requires supplementary oxygen, symptoms due to hypoxemia or oxygen saturation \<90% by pulse oximetry after a 2 minute walk) or in the opinion of the investigator any physiological state likely to cause systemic or regional hypoxemia
  5. Major surgery, other than diagnostic surgery, within 4 weeks prior to Day 1, without complete recovery
  6. Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy
  7. Treatment of pancreatic cancer with radiation therapy or surgery within 4 weeks prior to study entry
  8. Prior therapy with an hypoxic cytotoxin
  9. Subjects who participated in an drug or device study within 28 days prior to study entry
  10. Known active infection with , , or hepatitis
  11. Subjects who have exhibited allergic reactions to a structural compound, biological agent, or formulation (containing solutol and/or propylene glycol) similar to TH- 302
  12. Females who are pregnant or breast-feeding
  13. Concomitant disease or condition that could interfere with the conduct of the study, or that would, in the opinion of the investigator, pose an unacceptable risk to the subject in this study
  14. Unwillingness or inability to comply with the study protocol for any reason
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
214 participants (actual)

Study arms

  • Active comparator
    Gemcitabine

    Gemcitabine: 1,000 mg/m2 administered IV over 30 minutes on Days 1, 8 and 15 of a 28-day cycle

    Drug: Gemzar (Gemcitabine)

  • Experimental
    240 mg/m2 TH-302 + Gemcitabine

    TH-302: 240 mg/m2 administered IV over 30 minutes Day 1, 8, and 15 of each 28-day cycle Gemcitabine: 1,000 mg/m2 administered IV over 30 minutes on Days 1, 8 and 15 of a 28-day cycle

    Drug: Gemzar (Gemcitabine) · Drug: TH-302

  • Experimental
    340 mg/m2 TH-302 + Gemcitabine

    TH-302: 340 mg/m2 of TH-302 be administered IV over 30 minutes on Days 1, 8 and 15 of every 28-day cycle. Gemcitabine: 1,000 mg/m2 administered IV over 30 minutes on Days 1, 8 and 15 of a 28-day cycle

    Drug: Gemzar (Gemcitabine) · Drug: TH-302

Interventions

  • 1,000 mg/m2 administered IV over 30 minutes on Days 1, 8 and 15 of a 28-day cycle.

    Also known as: Gemcitabine

  • DrugTH-302

    240 mg/m2 of TH-302 will be administered IV over 30 minutes on Days 1, 8 and 15 of every 28-day cycle.

    Also known as: HAP, hypoxia activated prodrug

  • DrugTH-302

    340 mg/m2 of TH-302 will be administered IV over 30 minutes on Days 1, 8 and 15 of every 28-day cycle.

    Also known as: HAP, hypoxia activated prodrug

06

What researchers measure

Primary outcomes

  1. Progression-free Survival (PFS)

    Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions

    Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 1 year

07

Results

Posted Oct 25, 2017

Participant flow

Participant flow — Overall Study
MilestoneGemcitabine240 mg/m2 TH-302 + Gemcitabine340 mg/m2 TH-302 + Gemcitabine
Started697174
Completed192938
Not completed504236

Outcome measures

PrimaryProgression-free Survival (PFS)

Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions

Time frame:
From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 1 year
Reported as:
Median · days
Progression-free Survival (PFS)
daysGemcitabine240 mg/m2 TH-302 + Gemcitabine340 mg/m2 TH-302 + Gemcitabine
Progression-free Survival (PFS)111 (101 to 148)169 (130 to 211)183 (149 to 223)

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Gemcitabine—37/69 (53.6%)69/69 (100%)
240 mg/m2 TH-302 + Gemcitabine—35/71 (49.3%)71/71 (100%)
340 mg/m2 TH-302 + Gemcitabine—43/74 (58.1%)74/74 (100%)
Most frequent serious events
Showing 10 of 122
Most frequent serious events
EventGemcitabine240 mg/m2 TH-302 + Gemcitabine340 mg/m2 TH-302 + Gemcitabine
Pulmonary embolismRespiratory, thoracic and mediastinal disorders3/692/716/74
CholangitisHepatobiliary disorders5/692/712/74
PancytopeniaBlood and lymphatic system disorders0/691/715/74
Abdominal painGastrointestinal disorders3/694/715/74
VomitingGastrointestinal disorders2/693/715/74
PneumoniaInfections and infestations4/693/713/74
DehydrationMetabolism and nutrition disorders4/690/712/74
HypotensionVascular disorders4/690/711/74
Bile duct obstructionHepatobiliary disorders4/694/713/74
NauseaGastrointestinal disorders2/694/714/74
Most frequent other events
Showing 10 of 37
Most frequent other events
EventGemcitabine240 mg/m2 TH-302 + Gemcitabine340 mg/m2 TH-302 + Gemcitabine
FatigueGeneral disorders29/6942/7140/74
ThrombocytopeniaBlood and lymphatic system disorders20/6936/7143/74
AnaemiaBlood and lymphatic system disorders30/6936/7138/74
NeutropeniaBlood and lymphatic system disorders15/6927/7132/74
NauseaGastrointestinal disorders27/6926/7131/74
Oedema peripheralGeneral disorders28/6926/7131/74
DiarrhoeaGastrointestinal disorders17/6920/7127/74
StomatitisGastrointestinal disorders5/6913/7127/74
VomitingGastrointestinal disorders19/6915/7126/74
Decreased appetiteMetabolism and nutrition disorders16/6917/7125/74

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Gemcitabine240 mg/m2 TH-302 + Gemcitabine340 mg/m2 TH-302 + GemcitabineTotal
<=18 years0000
Between 18 and 65 years284336107
>=65 years412838107
Sex: Female, Male
Sex: Female, Male(Participants)Gemcitabine240 mg/m2 TH-302 + Gemcitabine340 mg/m2 TH-302 + GemcitabineTotal
Female29273288
Male404442126
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Gemcitabine240 mg/m2 TH-302 + Gemcitabine340 mg/m2 TH-302 + GemcitabineTotal
American Indian or Alaska Native0000
Asian4015
Native Hawaiian or Other Pacific Islander0000
Black or African American34512
White626467193
More than one race0000
Unknown or Not Reported0314
08

Study locations

59 sites
  • Birmingham Hematology and Oncology Associates, LLC
    Birmingham, Alabama 35223, United States
  • Mayo Clinic Arizona
    Scottsdale, Arizona 85259, United States
  • Arizona Oncology Associates, PC - HOPE
    Tucson, Arizona 85704, United States
  • University of Arizona
    Tucson, Arizona 85724, United States
  • Saint Edward Mercy Medical Center
    Fort Smith, Arkansas 72917, United States
  • Disney Family Cancer Center
    Burbank, California 91505, United States
  • Scripps Clinical Research Services
    La Jolla, California 92037, United States
  • UCLA Medical Center
    Los Angeles, California 90095, United States
  • Palo Alto Medical Foundation
    Mountain View, California 94040, United States
  • Los Palos Oncology and Hematology
    Salinas, California 93901, United States
  • Sharp Memorial Hospital
    San Diego, California 92123, United States
  • California Pacific Medical Center
    San Francisco, California 94115, United States
  • Rocky Mountain Cancer Centers
    Denver, Colorado 80218, United States
  • Hematology Oncology Associates, PC
    Stamford, Connecticut 06902, United States
  • Florida Cancer Institute - New Hope
    New Port Richey, Florida 34655, United States
  • Ocala Oncology Center
    Ocala, Florida 34471, United States
  • Martin Memorial Cancer Center
    Stuart, Florida 34994, United States
  • Atlanta Cancer Care
    Atlanta, Georgia 30342, United States
  • Loyola University Medical Center
    Maywood, Illinois 60153, United States
  • Carle Cancer Center
    Urbana, Illinois 61901, United States
  • Indiana University Melvin and Bren Simon Cancer
    Indianapolis, Indiana 46202, United States
  • Purchase Cancer Group
    Paducah, Kentucky 42002, United States
  • Medical Oncology
    Baton Rouge, Louisiana 70809, United States
  • Ochsner Cancer Institute
    New Orleans, Louisiana 70121, United States
  • LSU Health Sciences Center - Feist Weiller Cancer Center
    Shreveport, Louisiana 71130, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • University of Massachusetts Medical Center
    Worcester, Massachusetts 01655, United States
  • Virgina Piper Cancer Institute
    Minneapolis, Minnesota 55407, United States
  • Mayo Clinic Rochester
    Rochester, Minnesota 55905, United States
  • Hematology and Oncology Associates at BridgePoint
    Tupelo, Mississippi 38801, United States
  • Missouri Cancer Associates
    Columbia, Missouri 65201, United States
  • Montana Cancer Institute Foundation
    Missoula, Montana 59802, United States
  • Comprehensive Cancer Centers of Nevada
    Las Vegas, Nevada 89169, United States
  • Roswell Park Cancer Institute
    Buffalo, New York 14263, United States
  • New York Oncology Hematology, P.C.
    Hudson, New York 12534, United States
  • Cancer Care of Western North Carolina, PA
    Asheville, North Carolina 28801, United States
  • Alamance Oncology Hematolgy Associates
    Burlington, North Carolina 27599, United States
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
  • Carolina Oncology Specialists, PA
    Hickory, North Carolina 28602, United States
  • Emerywood Hematology and Oncology
    High Point, North Carolina 27262, United States
  • Signal Point Clinical Research Center
    Middletown, Ohio 45042, United States
  • Kaiser Permanente Northwest Region Oncology Hematology
    Portland, Oregon 97227, United States
  • Northwest Cancer Specialists, P.C.
    Portland, Oregon 97227, United States
  • Greater Philadelphia Cancer and Hematology Specialists, P.C.
    Philadelphia, Pennsylvania 19114, United States
  • Allegheny General Hospital
    Pittsburgh, Pennsylvania 15212, United States
  • University of Pittsburgh Medical Center
    Pittsburgh, Pennsylvania 15232, United States
  • Institute for Translational Oncology Research (ITOR)
    Greenville, South Carolina 29605, United States
  • Vanderbilt University Medical Center, Div. of Medical Oncology
    Nashville, Tennessee 37232, United States
  • Texas Oncology-Beaumont, Mamie McFaddin Ward Cancer Center
    Beaumont, Texas 77702, United States
  • Texas Oncology-Dallas Presbyterian Hospital
    Dallas, Texas 75231, United States
  • University of Texas Southwestern Medical Center at Dallas
    Dallas, Texas 75390, United States
  • Texas Oncology- Fort Worth - 12th Avenue
    Fort Worth, Texas 76104, United States
  • Texas Oncology-Seton Williamson
    Round Rock, Texas 78665, United States
  • Texas Oncology-Sherman
    Sherman, Texas 75090, United States
  • Texas Oncology-Wichita Falls Texoma Cancer Center
    Wichita Falls, Texas 76310, United States
  • Fairfax Northern Virginia Hematology Oncology, PC
    Fairfax, Virginia 22031, United States
  • Providence Everett Regional Medical Center, Cancer Research Dept.
    Everett, Washington 98201, United States
  • Columbia Basin Hematology and Oncology0
    Kennewick, Washington 99336, United States
  • University of Wisconsin
    Madison, Wisconsin 53792, United States
09

References and documents

Publications

  • Borad MJ, Reddy SG, Bahary N, Uronis HE, Sigal D, Cohn AL, Schelman WR, Stephenson J Jr, Chiorean EG, Rosen PJ, Ulrich B, Dragovich T, Del Prete SA, Rarick M, Eng C, Kroll S, Ryan DP. Randomized Phase II Trial of Gemcitabine Plus TH-302 Versus Gemcitabine in Patients With Advanced Pancreatic Cancer. J Clin Oncol. 2015 May 1;33(13):1475-81. doi: 10.1200/JCO.2014.55.7504. Epub 2014 Dec 15. PubMed 25512461 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2010, a primary completion of Sep 2013 and a completion of Dec 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2017, 4 years 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 11, 2010
First posted
Jun 15, 2010
Start
Jun 2010
Primary completionActual
Sep 2013
CompletionActual
Dec 2014
Results first posted
Oct 25, 2017
Last update
May 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01144455
Lead sponsor
ImmunoGenesis
Collaborators
PRA Health Sciences
Responsible party
Sponsor
First posted
Jun 15, 2010
Start date
Jun 2010
Primary completion
Sep 2013
Completion
Dec 2014
Results posted
Oct 25, 2017
Last update
May 11, 2025

Study contacts

Mitesh Borad, MD
principal investigator · Mayo Clinic
Shantan Reddy, MD
principal investigator · Lousiana Health Sciences Center - Shreveport

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TH 302

Start the discussion